{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:31:05Z","timestamp":1762176665076},"reference-count":26,"publisher":"American Society of Consultant Pharmacists","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Consultant Pharmacist"],"published-print":{"date-parts":[[2013,9,1]]},"DOI":"10.4140\/tcp.n.2013.584","type":"journal-article","created":{"date-parts":[[2013,9,6]],"date-time":"2013-09-06T01:07:43Z","timestamp":1378429663000},"page":"584-591","source":"Crossref","is-referenced-by-count":6,"title":["Tamoxifen and Depression: Drug Interactions in Breast Cancer"],"prefix":"10.4140","volume":"28","author":[{"given":"Katherine S.","family":"McMichael","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ericka L.","family":"Breden Crouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","published-online":{"date-parts":[[2013,9,5]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.genhosppsych.2007.10.008","article-title":"Major depression after breast cancer: a review of epidemiology and treatment","volume":"30","author":"JR Fann","year":"2008","journal-title":"Gen Hosp Psychiatry"},{"key":"2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1017\/S1478951508000606","article-title":"Depression in women with metastatic breast cancer: a review of the literature","volume":"6","author":"A Caplette-Gingras","year":"2008","journal-title":"Palliat Support Care"},{"key":"3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10549-007-9706-5","article-title":"Depression, quality of life and breast cancer: a review of the literature","volume":"110","author":"M Reich","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/jncimonographs\/lgh014","article-title":"Prevalence of depression in patients with cancer","volume":"32","author":"MJ Massie","year":"2004","journal-title":"J Natl Cancer Inst Monogr"},{"key":"5","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/cncr.22335","article-title":"Distress, psychiatric syndromes, and impairment of function in women with newly diagnosed breast cancer","volume":"107","author":"MT Hegel","year":"2006","journal-title":"Cancer"},{"key":"6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1176\/appi.psy.44.1.24","article-title":"Depression as a prognostic factor for breast cancer mortality","volume":"44","author":"K Hjerl","year":"2003","journal-title":"Psychosomatics"},{"key":"7","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2217\/fon.10.65","article-title":"Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: risk of breast cancer recurrence and mortality","volume":"6","author":"D Cronin-Fenton","year":"2010","journal-title":"Future Oncol"},{"key":"8","doi-asserted-by":"crossref","first-page":"570","DOI":"10.2174\/138920011795713706","article-title":"Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract","volume":"12","author":"F Caraci","year":"2011","journal-title":"Curr Drug Metab"},{"key":"9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1176\/appi.psy.48.3.205","article-title":"Tamoxifen treatment and newonset depression in breast cancer patients","volume":"48","author":"KC Lee","year":"2007","journal-title":"Psychosomatics"},{"key":"10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1524-4741.1999.98085.x","article-title":"The relationship between tamoxifen, estrogen, and depressive symptoms","volume":"5","author":"DS Thompson","year":"1999","journal-title":"Breast J"},{"key":"11","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1176\/appi.psy.50.2.162","article-title":"Acute tamoxifen-induced depression and its prevention with venlafaxine","volume":"50","author":"F Bourque","year":"2009","journal-title":"Psychosomatics"},{"key":"12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF00665698","article-title":"Clinical recognition and management of depression in node negative breast cancer patients treated with tamoxifen","volume":"27","author":"CK Cathcart","year":"1993","journal-title":"Breast Cancer Res Treat"},{"key":"13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1749-6632.1995.tb31394.x","article-title":"Mood disorder in women with early breast cancer taking tamoxifen, an estradiol receptor antagonist","volume":"761","author":"S Shariff","year":"1995","journal-title":"An expected or unexpected effect? Ann N Y Acad Sci"},{"key":"14","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/jnci\/93.21.1615","article-title":"Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study","volume":"93","author":"R Day","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/jnci\/dji005","article-title":"CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment","volume":"97","author":"Y Jin","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"16","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/jnci\/djg108","article-title":"Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine","volume":"95","author":"V Stearns","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"17","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2125.2009.03598.x","article-title":"Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions","volume":"69","author":"B Manheimer","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"18","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c693","article-title":"Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study","volume":"340","author":"CM Kelly","year":"2010","journal-title":"BMJ"},{"key":"19","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/sj.bjc.6604533","article-title":"Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram","volume":"99","author":"TL Lash","year":"2008","journal-title":"Br J Cancer"},{"key":"20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3109\/02841860903575273","article-title":"Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen","volume":"49","author":"TL Lash","year":"2010","journal-title":"Acta Oncol"},{"key":"21","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1177\/0091270004266618","article-title":"Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition","volume":"44","author":"D Lehmann","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"22","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.4088\/JCP.08r04856blu","article-title":"Interactions between tamoxifen and antidepressants via cytochrome P450 2D6","volume":"70","author":"JE Desmaris","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"23","unstructured":"Effexor prescribing information. Philadelphia, PA: Wyeth Pharmaceutical Inc.; revised November 2011."},{"key":"24","doi-asserted-by":"crossref","unstructured":"The ATAC (Arimidex, Tamoxifen Alone or in Combination) trialists' group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-10.","DOI":"10.1002\/cncr.11745"},{"key":"25","unstructured":"Arimidex prescribing information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; revised April 2011. 26."},{"key":"26","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1532-5415.2000.tb05005.x","article-title":"Update on electroconvulsive therapy in older adults","volume":"48","author":"KG Kelly","year":"2000","journal-title":"J Am Geriatr Soc"}],"container-title":["The Consultant Pharmacist"],"original-title":[],"deposited":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T21:24:59Z","timestamp":1498080299000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ingentaconnect.com\/content\/ascp\/tcp\/2013\/00000028\/00000009\/art00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,1]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9,1]]}},"alternative-id":["K07VT58J6N670221"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2013.584","relation":{},"ISSN":["0888-5109"],"issn-type":[{"value":"0888-5109","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9,1]]}}}